Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $8.7 million.

  • Allogene Therapeutics' Share-based Compensation fell 3537.01% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year decrease of 2165.87%. This contributed to the annual value of $51.7 million for FY2024, which is 2154.33% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Share-based Compensation of $8.7 million as of Q3 2025, which was down 3537.01% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Share-based Compensation peaked at $22.9 million during Q2 2022, and registered a low of $8.7 million during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $16.6 million (2023), whereas its average is $16.4 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Share-based Compensation surged by 3393.3% in 2021, and later tumbled by 3647.31% in 2024.
  • Over the past 5 years, Allogene Therapeutics' Share-based Compensation (Quarter) stood at $22.0 million in 2021, then fell by 21.74% to $17.2 million in 2022, then decreased by 11.67% to $15.2 million in 2023, then decreased by 15.49% to $12.9 million in 2024, then crashed by 32.79% to $8.7 million in 2025.
  • Its Share-based Compensation stands at $8.7 million for Q3 2025, versus $8.7 million for Q2 2025 and $12.2 million for Q1 2025.